Caredx Stock Fair Value Calculation – CareDx Reports Miss on Non-GAAP EPS and Revenue Estimates

Trending News 🌧️

CAREDX ($NASDAQ:CDNA): CareDx, Inc. (NASDAQ: CDNA) recently reported their Non-GAAP Earnings Per Share (EPS) and Revenue figures, which were lower than estimates. CareDx is a molecular diagnostics company that deals with transplant diagnostics and monitoring, helping clinicians diagnose and identify patients with heart, lung, and kidney transplants. Although CareDx did not meet the expectations of analysts, they are still optimistic about the future of the company.

They are continuing to focus on their transplant diagnostics and monitoring solutions, as well as expanding their reach in the healthcare industry. They believe that this will lead to increased revenues and profits in the future quarters.

Earnings

CAREDX reported their fourth quarter financial results of FY2022 ending on December 31st 2022. The company reported a total revenue of 82.38M USD, a 4.0% increase compared to the previous year. Over the last three years, CAREDX’s total revenue has grown from 58.64M USD to 82.38M USD.

However, the company reported a net income loss of 18.33M USD, missing its non-GAAP EPS and revenue estimates for the quarter. This is a disappointing result for CAREDX, as investors had hoped for higher profits.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Caredx. CareDx_Reports_Miss_on_Non-GAAP_EPS_and_Revenue_Estimates”>More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Caredx. CareDx_Reports_Miss_on_Non-GAAP_EPS_and_Revenue_Estimates”>More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Caredx. CareDx_Reports_Miss_on_Non-GAAP_EPS_and_Revenue_Estimates”>More…

Key Ratios Snapshot

Some of the financial key ratios for Caredx are shown below. CareDx_Reports_Miss_on_Non-GAAP_EPS_and_Revenue_Estimates”>More…

Market Price

The company’s stock opened at $8.8 and closed at $8.6, up by 0.7% from its previous closing price of $8.5. This was mainly due to a decrease in the company’s product sales. Despite this miss on its estimates, investors seemed to remain optimistic about the company’s long-term prospects and bid up its stock slightly this week. Time will tell whether CareDx can bounce back from this miss, but for now it is clear that analysts remain cautiously optimistic about the company’s performance in the quarters ahead. Live Quote…

Analysis – Caredx Stock Fair Value Calculation

At GoodWhale, we have conducted a thorough analysis of CAREDX‘s wellbeing. According to our proprietary Valuation Line, we have calculated that the intrinsic value of CAREDX shares is around $53.5. However, the stock is currently being traded at $8.6, making it a hugely attractive investment opportunity as it is undervalued by 83.9%. This marks a great chance to buy at a discounted price and reap the rewards in the long-term. More…

Peers

Its competitors are OpGen Inc, Stella Diagnostics Inc, and LungLife AI Inc.

– OpGen Inc ($NASDAQ:OPGN)

OpGen Inc is a biotechnology company that develops and commercializes genomic solutions for the healthcare industry. The company’s products and services include DNA sequencing, bioinformatics, and disease management. OpGen has a market cap of 9.75M as of 2022 and a ROE of -42.63%. The company’s products and services are used by healthcare providers to diagnose and treat diseases.

– Stella Diagnostics Inc ($OTCPK:SLDX)

LungLife AI Inc is a Canadian artificial intelligence company that uses machine learning to improve lung cancer diagnosis and treatment. The company has a market cap of 32.49M as of 2022 and a Return on Equity of -24.88%. LungLife AI’s technology is based on a deep learning algorithm that can identify patterns in CT scans that are associated with lung cancer. The company is working on a number of applications for its technology, including a lung cancer screening tool and a treatment planning tool.

Summary

CAREDX is a medical technology company that reported its latest earnings numbers. The company missed on both non-GAAP earnings per share (EPS), reporting -$0.11, and revenue, reporting $77.26 million. This missed the analysts’ expectations by $0.01 and $3.44 million respectively. Investors should closely monitor the company’s upcoming earnings reports to determine if it will be able to return to meeting expectations and turn its financial performance around.